Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Feasibility of Using a Subtherapeutic Dose of Piracetam as a Marker of Adherence to Therapy

NCT05918341 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT05918341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05918341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Feasibility of Using a Subtherapeutic Dose of Piracetam as a Marker of Adherence to Therapy
Lead sponsor
The Netherlands Cancer Institute
Phase
Phase 4
Overall status
Unknown status
Start date
July 3, 2023
Completion date
September 30, 2023
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

drug adherence marker